hotspot -WSS

hotspot

author：comprehensive 2025-10-01 21:35:11 - browse：75

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

knowledge

WSS

Why failed clinical trials don’t always spell doom for a new drug

The problem with charging patients to message their doctors

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Amylyx ALS drug failure raises questions and concerns

Novo Nordisk obesity pill bests Wegovy in early trial

What to know about Virgin Galactic's 1st mission taking paying customers to space

explore

hotspot

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Jerome Adams on the need for new antivirals for Covid

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The high cost of giving birth even with insurance

Change Healthcare payments predicted restored March 15

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why failed clinical trials don’t always spell doom for a new drug

Novavax promises a turnaround & Lilly roils the obesity market

First medicine developed to treat MASH expected to be approved soon

hotspot

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

RSV shot was 90% effective at preventing hospitalizations in kids

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

RSV shot was 90% effective at preventing hospitalizations in kids

Friends ask where James Watson's attitudes about race came from

In his State of the Union, Biden takes clear aim at 'Big Pharma'

entertainment

focus

knowledge

explore